Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

International Journal of Radiation Biology

Volumn 85, Issue 11, 2009, Pages 943-954

  Krause, Mechthild ^a   Gurtner, Kristin ^a   Deuse, Yvonne ^a   Baumann, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Biomarker; Chemotherapy; EGFR inhibition; Monoclonal antibody; Radiotherapy; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBX 1382 BS; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CHIMERIC ANTIBODY; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; GENETIC HETEROGENEITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NUTRITION; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70449509655     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553000903232835     Document Type: Review

References (85)

1. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen VA, Wouters BG, Lambin P. 2009. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. Journal of Nuclear Medicine 50:123-131.
2. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. 2002. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL- 8 and VEGF expression in human head and neck squamous cell carcinoma lines. International Journal of Cancer 99:538-548.
3. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. 1998. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. Journal of Biology and Chemistry 273:1568-1573. (Pubitemid 28133681)
4. Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP. 2007. EGFR-targeted anticancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiotherapy Oncology 83:238-248.
5. Baumann M, Krause M, Hill R. 2008. Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer 8:545-554.
6. Baumann M, Krause M, Zips D, Eicheler W, Dö rfler A, Ahrens J, Petersen C, Brü chner K, Hilberg F. 2003. Selective inhibition of the epidermal growth factor tyrosine kinase by BIBX1382BS improves growth delay but not local control after fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. International Journal of Radiation Biology 79:547-559.
7. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Science USA 104:20932-20937.
8. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. 2008. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research 14:7519-7525.
9. Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, Sonaglio C, Rossi A, Luppi G, Conte PF. 2009. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: A phase ii study in locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics 73:466-472.
10. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G. 2008. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti- EGFR drugs. British Journal of Cancer 98:923-930.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 354:567-578.
12. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland Jr KM, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology 26:5603-5609.
13. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. 2005. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 23:8646-8654.
14. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA. 2008. Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. International Journal of Radiation Oncology Biology Physics 71:676-681.
15. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. 2001. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research 7:1459-1465. (Pubitemid 32708703)
16. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer Stem Cells - Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Research 66:9339-9344.
17. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 351:337-345. (Pubitemid 38944402)
18. Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. 2006. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. Journal of Clinical Oncology 24:656-662.
19. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP. 2005a. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. Journal of Biology and Chemistry 280:31182-31189.
20. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. 2008. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNAPK. Molecular Cancer 7:69.
21. Dittmann K, Mayer C, Rodemann HP. 2005b. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiotherapy Oncology 76:157-161.
22. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. 2008. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu- DOTA-cetuximab in 5 cervical cancer cell lines. Journal of Nuclear Medicine 49:1472-1479.
23. Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. 2006. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiotherapy Oncology 80:178-184.
24. Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. International Journal of Radiation Biology 83:793-802.
25. Engelman JA, Cantley LC. 2008. A sweet new role for EGFR in cancer. Cancer Cell 13:375-436
26. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
27. Fan Z,Masui H, Altas I,Mendelsohn J. 1993. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research 53:4322-4328.
28. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D. 2006. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Molecular Cancer Therapy 5:209-218.
29. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, ManikhasGM, Von Pawel J. 2007. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall- cell lung cancer: The Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology 25:1545-1552.
30. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MW, Rennie P, Fandi A, Johnson DH. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. Journal of Clinical Oncology 22:777-784. (Pubitemid 41103588)
31. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K. 2009. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biology and Therapy 8:730-738.
32. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. 2009. A randomized phase iiib trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. Journal of Clinical Oncology 27:672-680.
33. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. Journal of Clinical Oncology 22:785-794. (Pubitemid 41103589)
34. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. 2005. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology 23:5892-5899.
35. Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG. 2008. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Research 68:8004-8013.
36. Huang SM, Harari PM. 2000. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clinical Cancer Research 6:2166-2174.
37. Huang SM, Li J, Armstrong EA, Harari PM. 2002. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Research 62:4300-4306.
38. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. 2008. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: Tissue effect predicts clinical response. American Journal of Clinical Oncology 31:329-334.
39. Kaplan O, Jaroszewski JW, Faustino PJ, Zugmaier G, Ennis BW, Lippman M, Cohen JS. 1990. Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. Journal of Biology and Chemistry 265:13641-13649.
40. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley DJ, Gandara DR. 2008. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. Journal of Clinical Oncology 26:2450-2456.
41. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. 2008. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818.
42. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. 2008. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE 3:e2881.
43. Krause M, Baumann M. 2008. Clinical biomarkers of kinase activity: Examples from EGFR inhibition trials. Cancer Metastasis Rev 27:387-402.
44. Krause M, Hessel F, Zips D, Hilberg F, Baumann M. 2004. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiotherapy Oncology 72:95-101.
45. Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, van der Kogel AJ, Thames HD, Baumann M. 2005a. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiotherapy Oncology 76:162-167.
46. Krause M, Prager J, Zhou X, Yaromina A, Dorfler A, Eicheler W, Baumann M. 2007. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells? Radiotherapy Oncology 83:316-325.
47. Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M. 2005b. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: A study on C225 in FaDu hSCC. Radiotherapy Oncology 74:109-115.
48. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, TakataM,Miyata M, Nakamoto M, Burioka N, Shimizu E. 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clinical Cancer Research 13:1552-1561.
49. Li L, Wang H, Yang ES, Arteaga CL, Xia F. 2008. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Research 68:9141-9146.
50. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY. 2005. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56:455-464.
51. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser S, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K. 2007. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annales of Oncology 18:738-744.
52. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. 2008. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. Journal of Clinical Oncology 26:4244-4252.
53. Maurel J, Martin-Richard M, Conill C, Sanchez M, Petriz L, Gines A, Miquel R, Gallego R, Cajal R, Ayuso C, Navarro S, Marmol M, Nadal C, Auge JM, Fernandez-Cruz L, Gascon P. 2006. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 66:1391-1398.
54. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK. 2007. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. International Journal of Radiation Oncology Biology Physics 67:568-572.
55. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25:1960-1966.
56. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. 2007. Implication of the insulin-like growth factor- IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clinical Cancer Research 13:2795-2803
57. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. 2006. Heterodimerization of insulin-like growth factor receptor/ epidermal growth factor receptor and induction of surviving expression counteract the antitumor action of erlotinib. Cancer Research 66:10100-10111
58. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S. 2009. EGFRvIII and DNA doublestrand break repair: A molecular mechanism for radioresistance in glioblastoma. Cancer Research 69:4252-4259.
59. Nasu S, Ang KK, Fan Z, Milas L. 2001. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. International Journal of Radiation Oncology Biology Physics 51:474-477.
60. Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisao C, Fontao K, Lima R, Herchenhorn D, Martins RG, Moralez GM, Small IA, Ferreira CG. 2008. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clinical Cancer Research 14:6324-6329.
61. Pignon JP, Bourhis J, Domenge C, Designe L. 2000. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta- Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955.
62. Pignon JP, le Maitre A, Bourhis J. 2007. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update. International Journal of Radiation Oncology Biology Physics 69:S112-114.
63. Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. 2007. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Research 67:665-673.
64. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S,Carson 3rdWE. 2007. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clinical Cancer Research 13:6419-6428.
65. Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W, Sauer R. 2008. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. International Journal of Radiation Oncology Biology Physics 70:1081-1086.
66. Rodemann HP, Dittmann K, Toulany M. 2007. Radiationinduced EGFR-signaling and control of DNA-damage repair. International Journal of Radiation Biology 83:781-791.
67. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. 2005. Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 353:123-132. (Pubitemid 41058344)
68. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris 3rd HA. 2008. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26:2311-2319.
69. Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. 2005. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Molecular Cancer Therapy 4:1417-1422.
70. Steinbach JP, Klumpp A, Wolburg H, Weller M. 2004. Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Research 64:1575-1578.
71. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA. 2008. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Journal of Thoracic Oncology 3:250-257.
72. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. 2008. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging 35:1089-1099.
73. Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, Yates D. 2001. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical Pharmacokinetics 40:297-306.
74. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537.
75. Thomas SM, Grandis JR. 2004. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Review 30:255-268.
76. Toulany M, Baumann M, Rodemann HP. 2007. Stimulated PI3K-AKT signaling mediated through ligand or radiationinduced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Molecular Cancer Research 5:863-872.
77. Toulany M, Dittmann K, Baumann M, Rodemann HP. 2005a. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiotherapy Oncology 74:117-129.
78. Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP. 2005b. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiotherapy Oncology 76:143-150.
79. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, Ono M. 2006. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Research 66:5346-5353.
80. Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM, Barbaro B, Innocente R, Rossi C, Boz G, Barba MC, Frattegiani A, Lupattelli M, Doglietto GB. 2008. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: A phase I and II Trial (1839IL/ 0092). International Journal of Radiation Oncology Biology Physics 72:644-649.
81. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 25:1658-1664.
82. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. 2008. Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine 359:1116-1127.
83. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. 2008. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13:385-393.
84. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. 2007. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires downregulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Research 67:5779-5788.
85. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. 2008. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptoractivating mutations. Cancer Research 68:9479-9487.